Publications

#35 [preprint]

Uridine cytidine kinases dictate the therapeutic response of molnupiravir via its bioactivation

Shu H, Sharma S, Alam S, Frank L, Tampere M, van Kuilenburg APB, Valerie NCK, Altun M, Chabes A, Rudd SG*, Zhang SM*.

bioRxiv. 2025.

*Corresponding authors

#34

Organocatalytic switches of DNA glycosylase OGG1 catalyze a highly efficient AP-lyase function

Kehler M, Zhou K, Kemas AM, Del Prado A, Hutchinson ES, Nairn EH, Varga M, Plattner Y, Zhong Y, Purewal-Sidhu O, Haslam J, Wiita E, Gildie H, Singerova K, Szaruga Z, Almlöf I, Hormann FM, Liu KC, Wallner O, Ortis F, Homan EJ, Gileadi O, Rudd SG, Stenmark P, de Vega M, Helleday T, D'Arcy-Evans ND, Lauschke VM, Michel M.

Chemistry. 2025. PMID: 40294343

#33

Nelarabine in T-cell acute lymphoblastic leukemia: intracelluar metabolism and molecular mode-of-action

Hormann FM & Rudd SG*

Leukemia. 2025. PMID: 39962329

* Corresponding author

#32

Understanding the interplay between dNTP metabolism and genome stability in cancer

Yagüe-Capilla M & Rudd SG*

Disease Models and Mechanisms. 2024. PMID: 39206868

* Corresponding author

#31 [preprint]

Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy

Wang J, Strauss R, Bartek J, Rudd SG*

bioRxiv. 2024.

* Corresponding author

#30

The N-terminal SAM domain of the dNTPase SAMHD1 is not required for inhibition by small molecule TH6342

Dirks C, Bwanika HC, Jemth AS, Zhang SM, Rudd SG*

Nucleosides Nucleotide Nucleic Acids. 2024. PMID: 38830230

* Corresponding author

#29

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel

Zhang SM*, Paulin CBJ, Shu H, Yagüe-Capilla M, Michel M, Marttila P, Ortis F, Bwanika HC, Dirks C, Papagudi Venkatram R, Wiita E, Jemth AS, Almlöf I, Loseva O, Hormann FM, Koolmeister T, Linde E, Lee S, Llona-Minguez S, Haraldsson M, Axelsson H, Strömberg K, Homan EJ, Scobie M, Lundbäck T, Helleday T, Rudd SG*

iScience. 2024. PMID: 38318365

* Corresponding authors

#28

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities

Rudd SG*

Cancer Chemotherapy and Pharmacology. 2023. PMID: 37452860

* Corresponding author

This article is part of the Emerging Leaders in Cancer Chemotherapy and Pharmacology collection

#27

Targeting the DNA damage response and repair through nucleotide metabolism

Helleday T*, Rudd SG*.

Molecular Oncology. 2022. PMID: 35583750

* Corresponding authors

#26

The prognostic and cliniopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis

Wang J, Hao S, Gu J, Rudd SG, Wang Y.

PeerJ. 2022. PMID: 35345582

#25

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Ceder S, Eriksson SE, Liang YY, Cheteh EH, Zhang SM, Fujihara KM, Bianchi J, Bykov VJN, Abrahmsen L, Clemons NJ, Nordlund P, Rudd SG, Wiman KG.

Cell Death & Disease. 2021. PMID: 34267184

#24

NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir

Zhang SM, Rehling D, Jemth AS, Throup A, Landázuri N, Almlöf I, Göttmann M, Valerie NCK, Borhade SR., Wakchaure P, Page BDG, Desroses M, Homan EJ, Scobie M, Rudd SG, Berglund UW, Söderberg-Nauclér C, Stenmark P, Helleday T.

Cell Chemical Biology. 2021. PMID: 34192523

#23

A High-Throughput Enzyme-Coupled Activity Assay to Probe Small Molecule Interaction with the dNTPase SAMHD1

Yagüe-Capilla M, Rudd SG*

Journal of Visualised Experiements. 2021. PMID: 33938897

* Corresponding author

#22

Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the strucural basis of thiopurine sensitivity

Rehling D, Zhang SM, Jemth AS, Koolmeister T, Throup A, Wallner I, Scaletti E, Moriyama T, Nishii R, Davies J, Desroses M, Rudd SG, Scobie M, Homan E, Warpman-Berglund U, Helleday T, Stenmark, P.

Journal of Biological Chemistry. 2021. PMID: 33753169

#21

Drug synergy scoring using minimal dose response matrices

Mäkelä P, Zhang SM, Rudd SG*

BMC Research Notes. 2021. PMID: 33468238

* Corresponding author

#20 [preprint]

SAMHD1 promotes oncogene-induced replication stress

Zhang SM, Calderón-Montaño JM, Rudd SG*

bioRxiv 2020.

* Corresponding author

#19

Development of a chemical probe against NUDT15

Zhang SM, Desroses M, Hagenkort A, Valerie NCK, Rehling D, Carter M, Wallner O, Koolmeister T, Throup A, Jemth AS, Almlöf I, Loseva O, Lundbäck T, Axelsson H, Regmi S, Sarno A, Krämer A, Pudelko L, Bräutigam L, Rasti A, Göttmann M, Wiita E, Kutzner J, Schaller T, Kalderén C, Cázares-Körner A, Page BDG, Krimpenfort R, Eshtad S, Altun M, Rudd SG, Knapp S, Scobie M, Homan EJ, Berglund UW, Stenmark P, Helleday T.

Nature Chemical Biology. 2020. PMID: 32690945

#18

MTH1 inhibitor TH588 disturbs mitotic progression and induces mitosis-dependent accumulation of genomic 8-oxodG

Rudd SG, Gad H, Sanjiv K, Amaral N, Hagenkort A, Groth P, Ström CE, Mortusewicz O, Warpman Berglund U, Helleday T.

Cancer Research. 2020. PMID: 32312836

#17

Cell Cycle Profiling Reveals Protein Oscillation, Phosphorylation, and Localization Dynamics

Herr P, Boström J, Rullman E, Rudd SG, Vesterlund M, Lehtiö J, Helleday T, Maddalo G, Altun M.

Molecular & Cellular Proteomics. 2020. PMID: 32051232

#16

Ribonucleotide Reductase Inhibitors Suppress SAMHD1 ara-CTPase Activity Enhancing Cytarabine Efficacy

Rudd SG*#, Tsesmetzis N#, Sanjiv K#, Paulin CB, Sandhow L, Kutzner J, Hed Myrberg I, Bunten SS, Axelsson H, Zhang SM, Rasti A, Mäkelä P, Coggins SA, Tao S, Suman S, Branca RM, Mermelekas G, Wiita E, Lee S, Walfridsson J, Schinazi RF, Kim B, Lehtiö J, Rassidakis GZ, Pokrovskaja Tamm K, Warpman-Berglund U, Heyman M, Grandér D, Lehmann S, Lundbäck T, Qian H, Henter JI, Schaller T, Helleday T, Herold N*.

EMBO Molecular Medicine. 2020. PMID: 31950591

* Corresponding author; # co-first author

Additional links:

Press release from Karolinska Institutet

News article from British Society for Heamatology

Tweet thread from Sean summarising the story

#15

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD

Blood Cancer Journal. 2018. PMID: 30341277

#14

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism

Tsesmetzis N, Paulin CBJ, Rudd SG*, Herold N*

Cancers. 2018. PMID: 30041457

*Corresponding author

#13

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells

Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth A-S, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T

Nature Communications. 2018. PMID:29343827

#12

With me or against me: Tumor suppressor and drug resistance activities of SAMHD1

Herold N#, Rudd SG#, Sanjiv K, Kutzner J, Myrberg IH , Paulin CBJ, Olsen TK, Helleday T, Henter JI, Schaller T

Experimental Hematology. 2017. PMID: 28502830

# co-first author

#11

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites

Herold N#, Rudd SG#, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, Schaller T

Cell Cycle. 2017. PMID: 28436707

# co-first author

#10

SAMHD1 is a barrier to antimetabolite-based cancer therapies

Rudd SG, Schaller T, Herold N.

Molecular & Cellular Oncology. 2017. PMID: 28401188

#9

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

Herold N#, Rudd SG#, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.

Nature Medicine. 2017. PMID: 28067901

# co-first author

Additional links:

Editors choice in Science Translational Medicine

Press release from Karolinska Institutet

#8

hMYH and hMTH1 cooperate for survival in mismatch repair defective T-cell acute lymphoblastic leukemia

Eshtad S, Mavajian Z, Rudd SG, Visnes T, Boström J, Altun M, Helleday T.

Oncogenesis. 2016. PMID: 27918552

#7

Validation and development of MTH1 inhibitors for treatment of cancer

Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, Chernobrovkin A, Manoilov A, Pateras IS, Rasti A, Jemth AS, Almlöf I, Loseva O, Visnes T, Einarsdottir BO, Gaugaz FZ, Saleh A, Platzack B, Wallner OA, Vallin KS, Henriksson M, Wakchaure P, Borhade S, Herr P, Kallberg Y, Baranczewski P, Homan EJ, Wiita E, Nagpal V, Meijer T, Schipper N, Rudd SG, Bräutigam L, Lindqvist A, Filppula A, Lee TC, Artursson P, Nilsson JA, Gorgoulis VG, Lehtiö J, Zubarev RA, Scobie M, Helleday T.

Annals of Oncology. 2016. PMID: 27827301